A carregar...
Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers
BACKGROUND: Treatment with apremilast has recently demonstrated clinically meaningful improvement in moderate hidradenitis suppurativa (HS). OBJECTIVE: To evaluate the change in expression of inflammatory markers in lesional skin of HS patients receiving apremilast 30 mg twice daily (n = 15) for 16 ...
Na minha lista:
| Publicado no: | J Eur Acad Dermatol Venereol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6590194/ https://ncbi.nlm.nih.gov/pubmed/30451329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.15354 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|